Breast Cancer

Tucatinib Added to First-Line HER2 Maintenance Prolongs Progression-Free Survival in Phase 3 Trial

Results presented at SABCS, published in JCO, show a clinically meaningful delay in progression with first-line maintenance tucatinib.